PMID- 36268012
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221024
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: 
      Epigenetic therapy.
PG  - 1034438
LID - 10.3389/fimmu.2022.1034438 [doi]
LID - 1034438
AB  - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only 
      curative treatment for patients with myeloid malignancies such as myelodysplastic 
      syndrome (MDS) and acute myeloid leukemia (AML). However, relapse and 
      graft-versus-host disease (GvHD) still affect the survival of patients who 
      receive allo-HSCT, and more appropriate therapeutic strategies should be applied 
      at all stages of transplantation to prevent these adverse events. The use of 
      epigenetics agents, such as hypomethylating agents (HMAs), has been explored to 
      decrease the risk of relapse by epigenetic modulation, which is especially 
      effective among AML patients with poor mutations in epigenetic regulators. 
      Furthermore, epigenetic agents have also been regarded as prophylactic methods 
      for GvHD management without abrogating graft versus leukemia (GvL) effects. 
      Therefore, the combination of epigenetic therapy and HSCT may optimize the 
      transplantation process and prevent treatment failure. Existing studies have 
      investigated the feasibility and effectiveness of using HMAs in the 
      pretransplant, transplant and posttransplant stages among MDS and AML patients. 
      This review examines the application of HMAs as a bridge treatment to reduce the 
      tumor burden and the determine appropriate dose during allo-HSCT. Within this 
      review, we also examine the efficacy and safety of HMAs alone or HMA-based 
      strategies in posttransplant settings for MDS and AML. Finally, we provide an 
      overview of other epigenetic candidates, which have been discussed in the 
      nontransplant setting.
CI  - Copyright (c) 2022 Yang, Wang, Huang, Huang, Wei, Wang and Zhang.
FAU - Yang, Guancui
AU  - Yang G
AD  - Medical Center of Hematology, Xinqiao Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical 
      University (Army Medical University), Chongqing, China.
AD  - Department of Hematology, Affiliated Hospital of North Sichuan Medical College, 
      Nanchong, China.
FAU - Wang, Xiang
AU  - Wang X
AD  - Medical Center of Hematology, Xinqiao Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical 
      University (Army Medical University), Chongqing, China.
FAU - Huang, Shiqin
AU  - Huang S
AD  - Medical Center of Hematology, Xinqiao Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical 
      University (Army Medical University), Chongqing, China.
FAU - Huang, Ruihao
AU  - Huang R
AD  - Medical Center of Hematology, Xinqiao Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical 
      University (Army Medical University), Chongqing, China.
FAU - Wei, Jin
AU  - Wei J
AD  - Department of Hematology, Affiliated Hospital of North Sichuan Medical College, 
      Nanchong, China.
FAU - Wang, Xiaoqi
AU  - Wang X
AD  - Medical Center of Hematology, Xinqiao Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical 
      University (Army Medical University), Chongqing, China.
FAU - Zhang, Xi
AU  - Zhang X
AD  - Medical Center of Hematology, Xinqiao Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
AD  - State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical 
      University (Army Medical University), Chongqing, China.
AD  - Department of Hematology, Affiliated Hospital of North Sichuan Medical College, 
      Nanchong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221004
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Humans
MH  - *Graft vs Host Disease/prevention & control
MH  - Transplantation, Homologous
MH  - *Myelodysplastic Syndromes/genetics/therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - *Leukemia, Myeloid, Acute/genetics/therapy
MH  - Recurrence
MH  - Epigenesis, Genetic
PMC - PMC9577610
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - epigenetic therapy
OT  - graft-versus-host disease
OT  - hematopoietic stem cell transplantation
OT  - myelodysplastic syndrome
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/22 06:00
MHDA- 2022/10/25 06:00
PMCR- 2022/01/01
CRDT- 2022/10/21 03:07
PHST- 2022/09/01 00:00 [received]
PHST- 2022/09/20 00:00 [accepted]
PHST- 2022/10/21 03:07 [entrez]
PHST- 2022/10/22 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1034438 [doi]
PST - epublish
SO  - Front Immunol. 2022 Oct 4;13:1034438. doi: 10.3389/fimmu.2022.1034438. 
      eCollection 2022.